Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

Mounjaro and Trulicity are two injectable medications that treat type 2 diabetes. Learn more about their key similarities, ...

The widely used anti-diabetes and weight loss drug Mounjaro, which contains the active ingredient tirzepatide, is now ...

【3 月 21 日，丹麦制药商诺和诺德(NVO.US)盘前下跌 1.7%。】 礼来公司周四在印度市场正式推出糖尿病及减肥药物 Mounjaro，这款明星产品自 2022 年在美国首次上市以来，全球销售额已突破 200 亿美元大关。 诺和诺德宣布计划在 ...

就在近日，礼来（LLY.N）又向市场投下了一颗重磅炸弹。公司在印度正式推出其糖尿病药物Mounjaro，并在第一时间获得了当地药品监管机构的批准。这个消息一经传出，礼来的股价瞬时拉升，盘初一度涨超2%，显示出市场对这一战略部署的热切反响。这款药物以5毫克小瓶装的4375卢比（约合50.67美元）和2.5毫克小瓶装的3500卢比（约合40.54美元）睁开了它的市场之旅。

Investing.com — 美国制药公司礼来已在印度推出其糖尿病和减肥药物Mounjaro，抢先于其竞争对手诺和诺德公司。这一举措发生在全球人口最多的国家印度面临肥胖症和糖尿病发病率上升的背景下。

格隆汇3月21日｜丹麦制药商诺和诺德(NVO.US)盘前下跌1.7%。消息上，礼来公司周四在印度市场正式推出糖尿病及减肥药物Mounjaro。这款明星产品自2022年在美国首次上市以来，全球销售额已突破200亿美元大关。诺和诺德宣布，计划在2026年 ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

Endometriosis is a gynaecological condition where tissue similar to the lining of the uterus grows outside the uterus. It can ...